Neuraxpharm Group, a Spain-based specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced on Monday the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed head of Commercial, Avendran Naidu, as the company continues to expand globally.
The launch of Neuraxpharm Australia follows the opening last year of Neuraxpharm Middle East and the establishment of affiliates in Brazil and Mexico in 2023. Based in Sydney, Neuraxpharm Australia will market the company's CNS products across Australia.
Neuraxpharm Australia will commercialise the prescription brands Nuvigil (armodafinil) and Modavigil (modafinil), both indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy, which were acquired by Neuraxpharm in December 2024.
The Australian affiliate will also bring to market BRIUMVI (ublituximab) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) after receiving approval from Australia's Therapeutic Goods Administration (TGA) in June 2025. Following a positive recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC) at its May 2025 meeting, Neuraxpharm says that it is now working to ensure eligible Australian patients can access BRIUMVI as soon as possible.
Ublituximab, developed by TG Therapeutics and licensed by Neuraxpharm ex-US, is a novel anti-CD20 monoclonal antibody approved in the United States, the European Union, the UK and Switzerland for the treatment of adult patients with RRMS that can be administered in a one-hour infusion, twice a year, following the starting dose. Additional CNS treatments from Neuraxpharm's portfolio are expected to follow.
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases
Silo Pharma regains compliance with Nasdaq minimum bid price
Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment
Bayer receives FDA approval for AMBELVIST MRI contrast agent
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
Verge Labs and Tenacia Biotechnology collaborate on advancing Tenacia's CNS pipeline
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Solvonis Therapeutics secures second US patent for PTSD compound series
Insilico Medicine and Tenacia expand AI-driven R&D collaboration
TheraCryf advances lead addiction programme to final preclinical stage
Collegium to acquire AZSTARYS from Corium Therapeutics
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
GenomOncology partners with WeTrials to support CNS cancer clinical trials